The week in pharma: action, reaction and insight – week to January 26, 2024
By Barbara Obstoj-Cardwell. Editor
New clinical trial data last week saw the shares of USA-based Gilead Sciences fall significantly as the company released disappointing Phase III results on its Trodelvy for lung cancer. Meanwhile, Ionis Pharma announced positive Phase III data on its donidalorsen for the treatment of hereditary angioedema (HAE). On the regulatory front, Legend Biotech announced in a Stock Exchange filing that the US Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to review its cell therapy Carvykti, which is being developed with Johnson & Johnson. Also of note, Dutch firm LAVA Therapeutics attracted positive investor support, with its shares rising 43%, following the news of a research collaboration with US pharma giant Merck & Co to trial its prostate cancer candidate LAVA-1207 in combination with Keytruda.
EVOKE-01 miss disappointing, but differentiation versus competitor evident
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze